- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01966328
A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment
March 29, 2016 updated by: Jeffrey S Heier
This research is studying the effect that Resolvine injection will have on patients with vitreomacular adhesion.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This research is studying the effect that Resolvine injection will have on patients with vitreomacular adhesion.
The investigators propose that intravitreal injection of Resolvine® 36% will: 1)Result in release of the vitreous adhesion to the macula in subjects with symptomatic vitreomacular attachment (VMA).
2)The Release of the VMA will create a measurable and favorable retinal change.
3) The release of vitreomacular traction may also result in visual acuity improvement within the short time frame of this study.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Retina-Vitreous Associates Medical Group
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ophthalmic Consultants of Boston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects, 18 years of age or older
- Willing and able to return for all study visits
- Willing and able to provide written informed consent
- Have symptomatic VMA.
- If both eyes are found to have Anatomic VMA the eye with lower visual acuity will be declared the study eye.
Exclusion Criteria:
- Subjects with high myopia in the study eye (axial length greater than or equal to 26.0 millimeters by ultrasound or spherical equivalent at the spectacle plane greater than -8.0 diopters)
- Subjects who have monocular vision or contralateral vision of 20/400 or worse BCVA in the non-study eye
- Subjects with a history of retinal detachment or tear in the study eye
- Subjects who have PVD in the study eye at Baseline (Grade III or greater PVD by B-scan)
- Subjects with unstable IOP (i.e. > 30 mmHg in the past six months) or IOP of > 21 mm Hg at enrollment, under medical control. Subjects may be on topical medications to control their IOP but may not stop or start a prostaglandin type or epinephrine based drug during the study.
- Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less than 6 months prior to study enrollment
- Subjects with a history of ocular trauma of any type in the study eye
- Subjects with media opacities or abnormalities that would preclude observation of the retina in the study eye per the investigator's judgment
- Subjects that have undergone any previous vitrectomy (either anterior or pars plana vitrectomy) in the study eye
- Subjects with a history of cataract surgery complications in the study eye
- Subjects that have undergone previous photocoagulation of the retina in the study eye
- Subjects with any evidence or history of either nonproliferative or proliferative diabetic retinopathy (NPDR) or (PDR) in the study eye
- Subjects with an anticipated need for cataract extraction in the study eye within the next 6 months
- Subjects with congenital eye malformations
- Subjects with recurrent uveitis or history of uveitis in either eye
- Subjects with ongoing ocular infection or inflammation in the study eye
- Subjects who are pregnant or nursing. Subjects of child bearing ages will undergo pregnancy testing.
- Subjects that are currently participating in any other investigational research study
- Subjects who are too ill to be likely to complete the entire study
- Subjects who have undergone major surgery within the last 6 months (systemic or ocular) or who are likely to require major surgery in the upcoming 6 months
- Subjects who are uncontrolled diabetics (HbA1/C > 10%) with significant morphological pathology at the time of enrollment
- Subjects with macular holes Stage 2 or greater as determined by OCT, B-scan ultrasound and clinical examination
- Subjects with epiretinal membrane (ERM) at the area of attachment as determined by OCT
- Subjects that have received other intravitreal injection therapy within thirty (30) days of treatment with Resolvine®
- Subjects that have received more than one Jetrea injection in the study eye
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 36% Resolvine
Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
|
36% Resolvine Intravitreal Injection
|
Active Comparator: 9% Resolvine
Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
|
9% Resolvine Intravitreal Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of 36% Resolvine Injection versus 9% Resolvine Injection
Time Frame: After all patients have completed the 6 month follow-up.
|
The primary objective of this study is to evaluate the safety of an active arm treated with Resolvine® 36%, which may contain up to two 100-microliter intravitreal injections, in comparison to a control arm treated with Resolvine 9%, which may contain up to two 100-microliter injections, in subjects with VMA.
Cumulative adverse event rates for each arm will be evaluated.
|
After all patients have completed the 6 month follow-up.
|
Efficacy of 36% Resolvine Injection versus 9% Resolvine Injection
Time Frame: After all patients have completed the 6 month follow-up
|
The primary objective of this study is to evaluate the efficacy of an active arm treated with Resolvine® 36%, which may contain up to two 100-microliter intravitreal injections, in comparison to a control arm treated with Resolvine 9%, which may contain up to two 100-microliter injections, in subjects with VMA.
Efficacy will be measured by the percent of patients whose VMA has released after treatment.
|
After all patients have completed the 6 month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inducement of PVD
Time Frame: After all patients have completed the 6 month follow-up
|
These analyses will compare the efficacy an active arm treated with Resolvine® 36%, which may contain up to two 100-microliter intravitreal injections, to a control arm treated with Resolvine 9%, which may contain up to two 100-microliter injections, to assess inducement of a more extensive PVD over the study period as demonstrated by Trese Grade III or higher B-Scan Ultrasound and OCT.
|
After all patients have completed the 6 month follow-up
|
Improved Eye Function
Time Frame: After all patients have completed the 6 month follow-up.
|
These analyses will assess a parameter of improved eye function as calculated by either the reduction in the retinal thickness of at least 10% over baseline at Day 0 as quantified by OCT, or an improvement in visual acuity of more than 10% over baseline at day 0 as quantified by ETDRS.
|
After all patients have completed the 6 month follow-up.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
October 14, 2013
First Submitted That Met QC Criteria
October 16, 2013
First Posted (Estimate)
October 21, 2013
Study Record Updates
Last Update Posted (Estimate)
March 31, 2016
Last Update Submitted That Met QC Criteria
March 29, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VMA-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitreomacular Traction
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); National Institutes of Health (NIH)CompletedVitreomacular TractionUnited States
-
ThromboGenicsCompletedVitreomacular TractionBelgium, Germany
-
University of Split, School of MedicineUnknown
-
Michael E. DeBakey VA Medical CenterBaylor College of MedicineUnknownEpiretinal Membrane | Vitreomacular TractionUnited States
-
Alcon ResearchCompletedVitreomacular Traction | Vitreomacular AdhesionAustralia
-
Alcon ResearchCompletedVitreomacular Traction | Vitreomacular Adhesion
-
Wagner Macula & Retina CenterThromboGenicsTerminatedVitreomacular Traction | Subretinal EdemaUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownGlaucoma | Posterior Vitreous Detachment | Vitreomacular Traction | Vitreopapillary TractionBelgium
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); National Institutes of Health (NIH)CompletedVitreomacular Traction (VMT) | Full-thickness Macular Holes (MH)United States
-
Universitaire Ziekenhuizen KU LeuvenCompletedMacular Holes | Vitreomacular Traction | Macular PuckerBelgium
Clinical Trials on 36% Resolvine Intravitreal Injection
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompletedNeovascular GlaucomaChina
-
Afyonkarahisar Health Sciences UniversityCompleted
-
Hemera BiosciencesWithdrawnGeographic Atrophy | Dry Age-related Macular Degeneration | Gene Therapy | Intravitreal Injection
-
Peregrine Eye and Laser InstituteCompletedDiabetic Macular Edema | Choroidal Neovascularization | Neovascular Age-related Macular Degeneration | Uveitic Macular Edema | Retinal Vein Occlusion With Macular EdemaPhilippines
-
Eye & ENT Hospital of Fudan UniversityUnknownDiabetic Retinopathy | Diabetic Macular Edema | Cataract Diabetic
-
Benha UniversityRecruiting
-
Xun XuPeking University; Zhongshan Ophthalmic Center, Sun Yat-sen University; Air Force... and other collaboratorsUnknownAge-Related Macular Degeneration | Polypoidal Choroidal Vasculopathy | Pathological Myopia | Conbercept | PharmacogenomicChina
-
Chengdu Kanghong Biotech Co., Ltd.Beijing DMS Pharma Ltd.; The Digital Angiography Reading Center (DARC)CompletedNeovascular Age-related Macular DegenerationChina
-
Instituto Universitario de Oftalmobiología Aplicada...University of ValladolidActive, not recruitingNon Arteritic Ischemic Optic NeuropathySpain